A Phase 3 interventional study of Eculizumab and Placebo in Refractory Generalized Myasthenia Gravis, sponsored by Alexion Pharmaceuticals, Inc.. Completed at 114 sites in 21 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-07-16.
Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Myasthenia Gravis by AstraZeneca — 8 open to participants now, 11 under way, 4 of them phase 3. Myasthenia Gravis · AstraZeneca.
Among the 19 studies in Myasthenia Gravis by AstraZeneca, this one is the 3rd largest by enrollment of the 13 interventional ones that give a count, is the only one that started in 2013, is one of 9 in phase 3, and was the 2nd registered.
331 studies on the registry are indexed under Myasthenia Gravis; 145 are open to participants now.
Browse Myasthenia Gravis studies →8 of the 19 studies in Myasthenia Gravis by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:
Alexion Pharmaceuticals, Inc. · Sites in China
Ages 18–130
Alexion Pharmaceuticals, Inc. · Sites in United States, Germany, Italy and 1 more country
Ages 18+
AstraZeneca · Sites in Russia
Ages 18+
Alexion Pharmaceuticals, Inc. · Sites in Italy
Ages 18+
AstraZeneca · Sites in Poland
Ages 18+
By country, each count listing its studies:
Of the 104 Myasthenia Gravis studies recruiting now, 64 (62%) set no upper age limit and 23 (22%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 1 started in 2013.
This study's enrollment of 125 is above the median of 44 across 218 interventional studies indexed under Myasthenia Gravis.
Median enrollment 20 across the 13 interventional studies, 263 across the 6 observational. Of the 7 that completed or were terminated, 6 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Alexion Pharmaceuticals, Inc., one of the names counted as AstraZeneca. Under that name alone:
Alexion Pharmaceuticals, Inc. is the lead sponsor of 255 studies on the registry; 23 are open to participants now.
Of its 101 completed or terminated interventional studies of FDA-regulated products, 75 (74%) have results posted.
4 of the studies in Myasthenia Gravis by AstraZeneca that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06607627Phase 3Alexion Pharmaceuticals, Inc.PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis | 2026-12-15 |
| NCT07596784Phase 3Alexion Pharmaceuticals, Inc.Efficacy and Safety of Ravulizumab in Chinese Adults Participants With Generalized Myasthenia Gravis (gMG) | 2027-08-24 |
| NCT06967480Alexion Pharmaceuticals, Inc.Early Ravulizumab Treatment Of Anti- AChR Antibody-Positive Generalized Myasthenia Gravis | 2027-06-30 |
| NCT07221838Alexion Pharmaceuticals, Inc.A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab | 2027-08-27 |
Add all 4 to your calendar (.ics) → With an account.
Among the 19 studies in Myasthenia Gravis by AstraZeneca, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine if eculizumab is safe and effective for the treatment of refractory generalized Myasthenia Gravis.
Key Inclusion Criteria:
Diagnosis of MG made by the following tests:
One of the following:
Subjects who have:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological/Vaccine: Eculizumab; Induction phase: 3 vials of study drug (equivalent to 900 mg of eculizumab) weekly for 4 doses (every 7 days ± 2 days) followed by 4 vials of study drug (equivalent to 1200 mg of eculizumab) 1 week later for the fifth dose (Week 4); Maintenance phase: 4 vials of study drug (equivalent to 1200 mg of eculizumab) every 2 weeks (14 days ± 2 days) from the fifth dose onwards (Week 6 through Week 26).
Biological: Eculizumab
Placebo contains the same buffer components without the active ingredient; Induction phase: 3 vials of study drug (placebo) weekly for 4 doses (every 7 days ± 2 days) followed by 4 vials of study drug (placebo) 1 week later for the fifth dose (Week 4); Maintenance phase: 4 vials of study drug (placebo) every 2 weeks (14 days ± 2 days) from the fifth dose onwards (Week 6 through Week 26).
Drug: Placebo
Induction Phase: 900 mg IV weekly X 4 Maintenance Phase: 1200 mg IV every 2 weeks during Weeks 4-26
Placebo
Myasthenia Gravis Activities of Daily Living Profile (MG-ADL): Change From Baseline in MG-ADL Total Score at Week 26 by Worst-Rank Analysis of Covariance (ANCOVA)
In the Worst-Rank analysis, the 125 total patients were ranked from best outcome (rank/score of 1) to worst outcome (rank/score of 125).
Time frame: End of study (Week 26)
| Milestone | Eculizumab | Placebo |
|---|---|---|
| Started | 62 | 63 |
| Completed | 57 | 61 |
| Not completed | 5 | 2 |
In the Worst-Rank analysis, the 125 total patients were ranked from best outcome (rank/score of 1) to worst outcome (rank/score of 125).
| scores on a scale | Eculizumab | Placebo |
|---|---|---|
| Myasthenia Gravis Activities of Daily Living Profile (MG-ADL): Change From Baseline in MG-ADL Total Score at Week 26 by Worst-Rank Analysis of Covariance (ANCOVA) | 56.6 ± 4.53 | 68.3 ± 4.49 |
Collected over 26 weeks (Study Period) + 8 weeks (Follow-up Period for subjects who discontinued the Study Period or completed the Study Period but did not enroll in the ECU-MG-302 extension trial). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Eculizumab | 0/62 (0%) | 9/62 (14.5%) | 52/62 (83.9%) |
| Placebo | 0/63 (0%) | 18/63 (28.6%) | 53/63 (84.1%) |
| Event | Eculizumab | Placebo |
|---|---|---|
| Myasthenia gravisNervous system disorders | 5/62 | 8/63 |
| PyrexiaGeneral disorders | 2/62 | 0/63 |
| Upper respiratory tract infectionInfections and infestations | 0/62 | 2/63 |
| Metastases to boneNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/62 | 0/63 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/62 | 0/63 |
| LymphopeniaBlood and lymphatic system disorders | 1/62 | 0/63 |
| Myasthenia gravis crisisNervous system disorders | 1/62 | 0/63 |
| Intestinal perforationGastrointestinal disorders | 1/62 | 0/63 |
| BacteraemiaInfections and infestations | 1/62 | 0/63 |
| DiverticulitisInfections and infestations | 1/62 | 0/63 |
| Event | Eculizumab | Placebo |
|---|---|---|
| HeadacheNervous system disorders | 10/62 | 12/63 |
| Upper respiratory tract infectionInfections and infestations | 10/62 | 10/63 |
| NasopharyngitisInfections and infestations | 9/62 | 10/63 |
| NauseaGastrointestinal disorders | 8/62 | 9/63 |
| DiarrhoeaGastrointestinal disorders | 8/62 | 8/63 |
| Back painMusculoskeletal and connective tissue disorders | 5/62 | 6/63 |
| ContusionInjury, poisoning and procedural complications | 5/62 | 2/63 |
| DizzinessNervous system disorders | 5/62 | 5/63 |
| MyalgiaMusculoskeletal and connective tissue disorders | 5/62 | 2/63 |
| Oral herpesInfections and infestations | 5/62 | 0/63 |
| Age, Continuous(years) | Eculizumab | Placebo | Total |
|---|---|---|---|
| Mean | 47.5 ± 15.66 | 46.9 ± 17.98 | 47.2 ± 16.80 |
| Sex: Female, Male(Participants) | Eculizumab | Placebo | Total |
|---|---|---|---|
| Female | 41 | 41 | 82 |
| Male | 21 | 22 | 43 |
Showing the first 100 of 114 sites across 21 countries. Choose a country and city above to see the rest.
Plan to share: No
The record gives a start of Dec 2013, a primary completion of Feb 2016 and a completion of Jun 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2018, 2 years after primary completion. A results delay was requested in Mar 2017.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Eculizumab
Alexion Pharmaceuticals, Inc. →